Hong Kong · Delayed Price · Currency is HKD Nanjing Leads Biolabs Company Description
Nanjing Leads Biolabs Co., Ltd., a clinical-stage biotechnology company, engages in the research, development, and commercialisation of novel antibody drugs worldwide.
It develops therapies in oncology, autoimmune, and other severe diseases. The company’s lead product LBL-024, a PD-L1/4-1BB bispecific antibody for extra-pulmonary neuroendocrine carcinoma, as well as LBL-034, LBL-033, and LBL-007.
In addition, it develops LeadsBody platform, a portfolio of CD3 T-cell engagers that demonstrate anti-tumor efficacy and safety in preclinical/clinical studies; X-body platform, a 4-1BB/PD-L1 bispecific antibody.
The company also develops antibody drugs for anti-tumor, autoimmune and infectious diseases and establishes tumor immunoassay.
The company was founded in 2012 and is headquartered in Nanjing, China.
| Country | China |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 192 |
| CEO | Xiaoqiang Kang |
Contact Details
Address: Building 03 Nanjing, 210019 China | |
| Phone | 86 25 8337 8099 |
| Website | leadsbiolabs.com |
Stock Details
| Ticker Symbol | 9887 |
| Exchange | Hong Kong Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CNY |
| ISIN Number | CNE1000070H8 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Xiaoqiang Kang | Co-Founder, Executive Chairman, GM and Chief Executive Officer |
| Dr. Shoupeng Lai | Co-Founder, Chief Strategic Officer, Executive Vice President and Executive Director |
| Honggang Zuo | Chief Financial Officer, Secretary of the Board and Executive Director |
| Dr. Hong Ling M.D., Ph.D. | Senior Vice President and Chief Scientific Officer |
| Dr. Shengli Cai | Chief Medical Officer |
| Qing-lai Zhu | Vice President and Head of Global Business Development |
| Xuegen Jian | Joint Company Secretary |